Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200000, China
NCT Number: NCT05795751
COVID-19 is an infectious disease caused by a virus called SARS-CoV-2. The spread rate and mortality rate of the virus have had a significant impact on global health and economic systems. Comprehensive treatment and supportive care are required to help COVID-19 patients recover. During the treatment of COVID-19, the respiratory system of patients may be affected, and measures need to be taken to support respiratory function. Currently, awake prone positioning(APP) is an effective method for treating respiratory failure when mechanical ventilation is not feasible or unavailable.
In the prone position, the patient's face is facing the ground, the chest is sinking, and the abdomen is rising. This posture can improve alveolar ventilation and blood flow distribution, reduce pulmonary edema and pulmonary vascular resistance. In addition, the prone position can also improve the coordination of respiratory muscles, promote pulmonary expectoration, and increase functional residual capacity. Although the prone position has been widely used, there is still some controversy over when to use it. Some studies have shown that using the APP for early-stage COVID-19 patients can reduce mortality rates and respiratory dependence time, while others believe that using the APP in the later stages may increase the risk of lung injury.
Therefore, it is necessary to further study when to use the APP and its impact on treatment effectiveness and safety. Such research may need to consider multiple factors, such as the patient's clinical symptoms, the severity of lung lesions, lung function indicators, and the duration of using the prone position. Determining the optimal time to use the APP will help guide clinical physicians to better apply this treatment strategy in the treatment of COVID-19 patients. In addition, the prone position can also be used in the treatment of other respiratory system diseases, so relevant research can also provide references and inspiration for the treatment of other diseases.
The goal of this observational study is to learn about the details which might optimize the effect of APP in COVID-19 patients. The main questions it aims to answer are:
* The optimal time to start in the prone position * the optimal duration of APP treatment * the strategies to improve the tolerance of the awake prone position
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Shanghai, Shanghai Municipality, 200000, China
Retrospectively collect relevant data from the electronic medical records of COVID-19 patients who were admitted to the research center from December 2022 to February 2023.
Convenient sampling of COVID-19 patients admitted to the research center from December 2022 to February 2023.
Inclusion criteria
Exclusion criteria
4.1 Baseline data: Gender, age, comorbidities, body mass index (BMI), smoking status, use of anti-Covid-19 drugs (Paxlovid and Azvudine), use of corticosteroids, and radiological results, etc., as baseline and demographic data.
4.2 Data related to awake prone positioning: Time from admission to first use of awake prone positioning, oxygen delivery method and oxygen concentration at first use of awake prone positioning, peripheral oxygen saturation during use of awake prone positioning, systolic blood pressure and respiratory rate at first use of awake prone positioning, duration of daily use of awake prone positioning, total number of days using awake prone positioning, achievement of awake prone positioning goals, acceptance of maintenance measures for awake prone positioning, changes in oxygen delivery method and oxygen concentration after first use of awake prone positioning, and adverse events caused by awake prone positioning (dislodged catheter, skin injury, and gastrointestinal reactions).
4.3 primary outcome: Mortality rate.
4.4 Secondary outcomes: Intubation, upgrading of oxygen supply equipment, deterioration of respiratory failure, and length of hospital stay.
7.1 Establish a unified case information collection register. Before collecting data, all data collectors will receive unified training to clarify the concept of data collection and screening standards, ensuring the consistency of data collection.
7.2 Data collection will be carried out simultaneously by two individuals and entered into the electronic medical record information collection register to ensure accuracy.
7.3 If any unresolved or uncertain issues arise during the data collection process, timely communication with the principal investigator will be conducted to ensure consistency of the information.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From December 2022 to February 2023
hospital mortality
Time frame: From December 2022 to February 2023
intubation after APP, escalation of respiratory support,Deterioration of respiratory failure
Ruijin Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06860282
COVID-19, Coronaviridae Infections
Hangzhou, Zhejiang, China
View Trial DetailsNCT05097677
COVID-19, COVID-19 Acute Bronchitis
Antwerp, Belgium
View Trial Details